• 1
    Willett WC,Polk BF,Morris JS,Stampfer MJ,Pressel S,Rosner B,Taylor JO,Schneider K,Hames CG. Prediagnostic serum selenium and risk of cancer. Lancet 1983; 2: 1304.
  • 2
    Clark LC,Alberts DS. Selenium and cancer: risk or protection? J Natl Cancer Inst 1995; 87: 4735.
  • 3
    Nyman DW,Suzanne Stratton M,Kopplin MJ,Dalkin BL,Nagle RB,Jay Gandolfi A. Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev 2004; 28: 816.
  • 4
    Brooks JD,Metter EJ,Chan DW,Sokoll LJ,Landis P,Nelson WG,Muller D,Andres R,Carter HB. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001; 166: 20348.
  • 5
    El-Bayoumy K. The protective role of selenium on genetic damage and on cancer. Mutat Res 2001; 475: 12339.
  • 6
    Clark LC,Dalkin B,Krongrad A,Combs GF,Jr,Turnbull BW,Slate EH,Witherington R,Herlong JH,Janosko E,Carpenter D,Borosso C,Falk S, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998; 81: 7304.
  • 7
    Duffield-Lillico AJ,Reid ME,Turnbull BW,Combs GF,Jr,Slate EH,Fischbach LA,Marshall JR,Clark LC. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002; 11: 6309.
  • 8
    Rayman MP. The importance of selenium to human health. Lancet 2000; 356: 23341.
  • 9
    Klein EA,Thompson IM,Lippman SM,Goodman PJ,Albanes D,Taylor PR,Coltman C. SELECT: the selenium and vitamin E cancer prevention trial. Urol Oncol 2003; 21: 5965.
  • 10
    Costello AJ. A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: rationale, recruitment, and design issues. Urology 2001; 57(4 Suppl 1): 1824.
  • 11
    Hoque A,Albanes D,Lippman SM,Spitz MR,Taylor PR,Klein EA,Thompson IM,Goodman P,Stanford JL,Crowley JJ,Coltman CA,Santella RM. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control 2001; 12: 62733.
  • 12
    Oberley TD,Zhong W,Szweda LI,Oberley LW. Localization of antioxidant enzymes and oxidative damage products in normal and malignant prostate epithelium. Prostate 2000; 44: 14455.
  • 13
    Waters DJ,Shen S,Cooley DM,Bostwick DG,Qin J,Combs GF,Jr,Glickman LT,Oteham C,Schlittler D,Morris JS. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst 2003; 95: 23741.
  • 14
    Zhong W,Oberley TD. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 2001; 61: 70718.
  • 15
    El-Bayoumy K,Richie JP,Jr,Boyiri T,Komninou D,Prokopczyk B,Trushin N,Kleinman W,Cox J,Pittman B,Colosimo S. Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study. Cancer Epidemiol Biomarkers Prev 2002; 11: 145965.
  • 16
    Jiang C,Wang Z,Ganther H,Lu J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002; 1: 105966.
  • 17
    Jiang C,Wang Z,Ganther H,Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001; 61: 306270.
  • 18
    Sinha R,El-Bayoumy K. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets 2004; 4: 1328.
  • 19
    Sinha R,Medina D. Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial cells. Carcinogenesis 1997; 18: 15417.
  • 20
    Ip C,Dong Y. Methylselenocysteine modulates proliferation and apoptosis biomarkers in premalignant lesions of the rat mammary gland. Anticancer Res 2001; 21: 8637.
  • 21
    Jacob C,Maret W,Vallee BL. Selenium redox biochemistry of zinc-sulfur coordination sites in proteins and enzymes. Proc Natl Acad Sci USA 1999; 96: 191014.
  • 22
    Jozsef L,Filep JG. Selenium-containing compounds attenuate peroxynitrite-mediated NF-κB and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes. Free Radic Biol Med 2003; 35: 101827.
  • 23
    El-Bayoumy K,Narayanan BA,Desai DH,Narayanan NK,Pittman B,Amin SG,Schwartz J,Nixon DW. Elucidation of molecular targets of mammary cancer chemoprevention in the rat by organoselenium compounds using cDNA microarray. Carcinogenesis 2003; 24: 150514.
  • 24
    El-Bayoumy K,Chae YH,Upadhyaya P,Meschter C,Cohen LA,Reddy BS. Inhibition of 7,12-Dimethylbenz(a)anthracene-induced tumors and DNA adduct formation in the mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound 1,4-phenylenebis(methylene)selenocyanate. Cancer Res 1992; 52: 24027.
  • 25
    Ip C,Lisk DJ,Ganther HE. Activities of structurally-related lipophilic selenium compounds as cancer chemopreventive agents. Anticancer Res 1998; 18: 401925.
  • 26
    Wu HC,Hsieh JT,Gleave ME,Brown NM,Pathak S,Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994; 57: 40612.
  • 27
    Lakritz J,Plopper CG,Buckpitt AR. Validated high-performance liquid chromatography-electrochemical method for determination of glutathione and glutathione disulfide in small tissue samples. Anal Biochem 1997; 247: 638.
  • 28
    Fernandez-Checa JC. Redox regulation and signaling lipids in mitochondrial apoptosis. Biochem Biophys Res Commun 2003; 304: 4719.
  • 29
    Das KC. c-Jun NH2-terminal kinase-mediated redox-dependent degradation of IκB: role of thioredoxin in NF-κB activation. J Biol Chem 2001; 276: 466270.
  • 30
    Hyland P,Barnett C,Pawelec G,Barnett Y. Age-related accumulation of oxidative DNA damage and alterations in levels of p16(INK4a/CDKN2a), p21(WAF1/CIP1/SDI1) and p27(KIP1) in human CD4+ T cell clones in vitro. Mech Ageing Dev 2001; 122: 115167.
  • 31
    Harris MH,Vander Heiden MG,Kron SJ,Thompson CB. Role of oxidative phosphorylation in Bax toxicity. Mol Cell Biol 2000; 20: 35906.
  • 32
    Roy S,Khanna S,Bickerstaff AA,Subramanian SV,Atalay M,Bierl M,Pendyala S,Levy D,Sharma N,Venojarvi M,Strauch A,Orosz CG, et al. Oxygen sensing by primary cardiac fibroblasts: a key role of p21(Waf1/Cip1/Sdi1). Circ Res 2003; 92: 26471.
  • 33
    Gopalakrishna R,Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med 2000; 28: 134961.
  • 34
    Mostert V,Dreher I,Kohrle J,Wolff S,Abel J. Modulation of selenoprotein P expression by TGF-β(1) is mediated by Smad proteins. Biofactors 2001; 14: 13542.
  • 35
    Stapleton SR,Garlock GL,Foellmi-Adams L,Kletzien RF. Selenium: potent stimulator of tyrosyl phosphorylation and activator of MAP kinase. Biochim Biophys Acta 1997; 1355: 25969.
  • 36
    Ozen M,Pathak S. Genetic alterations in human prostate cancer: a review of current literature. Anticancer Res 2000; 20: 190512.
  • 37
    Lu J,Jiang C. Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid Redox Signal 2005; 7: 171527.
  • 38
    Cooper AJL,Pinto JT. Cysteine S-conjugate β-lyases. Amino Acids 2006; 30: 115.
  • 39
    Rooseboom M,Vermeulen NPE,van Hemert N,Commandeur JNM. Bioactivation of chemopreventive selenocysteine Se-conjugates and related amino acids by amino acid oxidases—novel route of metabolism of selenoamino acids. Chem Res Toxicol 2001; 14: 9961005.
  • 40
    Yeung F,Li X,Ellett J,Trapman J,Kao C,Chung LW. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 2000; 275: 4084655.
  • 41
    Dixon SC,Knopf KB,Figg WD. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 2001; 53: 7391.
  • 42
    Bhamre S,Whitin JC,Cohen HJ. Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth. Prostate 2003; 54: 31521.
  • 43
    Cho SD,Jiang C,Malewicz B,Dong Y,Young CY,Kang KS,Lee YS,Ip C,Lu J. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 2004; 3: 60512.
  • 44
    Dong Y,Lee SO,Zhang H,Marshall J,Gao AC,Ip C. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 2004; 64: 1922.
  • 45
    El-Bayoumy K,Rao CV,Reddy BS. Multiorgan sensitivity to anticarcinogenesis by the organoselenium 1,4-phenylenebis(methylene)selenocyanate. Nutr Cancer 2001; 40: 1827.
  • 46
    Gladyshev VN,Factor VM,Housseau F,Hatfield DL. Contrasting patterns of regulation of the antioxidant selenoproteins, thioredoxin reductase, and glutathione peroxidase, in cancer cells. Biochem Biophys Res Commun 1998; 251: 48893.
  • 47
    Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 1999; 20: 165766.
  • 48
    Wang Z,Jiang C,Ganther H,Lu J. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling. Cancer Res 2001; 61: 71718.
  • 49
    Jiang C,Ganther H,Lu J. Monomethyl selenium–specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog 2000; 29: 23650.
  • 50
    Baines A,Taylor-Parker M,Goulet AC,Renaud C,Gerner EW,Nelson MA. Selenomethionine inhibits growth and suppresses cyclooxygenase-2 (COX-2) protein expression in human colon cancer cell lines. Cancer Biol Ther 2002; 1: 3704.
  • 51
    Hockenbery DM,Oltvai ZN,Yin XM,Milliman CL,Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 24151.
  • 52
    Meyer M,Schreck R,Baeuerle PA. H2O2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant responsive factor. EMBO J 1993; 12: 200515.
  • 53
    Powis G,Gasdaska JR,Baker A. Redox signaling and the control of cell growth and death. In: Sies H, ed. Antioxidants in disease mechanisms and therapy. Advances in Pharmacology, vol. 38. New York: Academic Press, 1997, pp. 32959.
  • 54
    Klatt P,Lamas S. Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur J Biochem 2000; 267: 492844.
  • 55
    Wu Y,Zhang H,Dong Y,Park YM,Ip C. Endoplasmic reticulum stress signal mediators are targets of selenium action. Cancer Res 2005; 65: 90739.
  • 56
    Kawamori T,El-Bayoumy K,Ji BY,Rodriguez JG,Rao CV,Reddy BS. Evaluation of benzyl selenocyanate glutathione conjugate for potential chemopreventive properties in colon carcinogenesis. Int J Oncol 1998; 13: 2934.
  • 57
    El-Bayoumy K,Upadhyaya P,Sohn OS,Rosa JG,Fiala ES. Synthesis and excretion profile of 1,4-[14C]phenylenebis(methylene)selenocyanate in the rat. Carcinogenesis 1998; 19: 16037.
  • 58
    Bettuzzi S,Scaltriti M,Caporali A,Brausi M,D'Arca D,Astancolle S,Davalli P,Corti A. Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study. Cancer Res 2003; 63: 346972.
  • 59
    Cronauer MV,Schulz WA,Burchardt T,Ackermann R,Burchardt M. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 2004; 23: 35419.
  • 60
    Narayanan BA,Narayanan NK,Re GG,Nixon DW. Differential expression of genes induced by resveratrol in LNCaP cells: p53-mediated molecular targets. Int J Cancer. 2003; 104: 20412.
  • 61
    Jiang C,Hu H,Malewicz B,Wang Z,Lu J. Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells. Mol Cancer Ther 2004; 3: 87784.